Etanercept in erythema nodosum leprosum
AUTOR(ES)
Santos, Julia Rocha Silva, Vendramini, Dâmia Leal, Nery, José Augusto da Costa, Avelleira, João Carlos Regazzi
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2017-08
RESUMO
Abstract: One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
Documentos Relacionados
- Polymorphonuclear cell function in the various polar types of leprosy and erythema nodosum leprosum.
- Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum.
- Infection of the lymphatic system by Aureobasidium pullulans in a patient with erythema nodosum leprosum
- Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine
- Critical residues of the Mycobacterium leprae LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions.